Screener
ImmunityBio, Inc. IBRX Interest Expense
Interest Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseOther.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Change in fair value of warrant liabilities | (295,413) | (448) |
| Change in fair value of related-party convertible note | (236,625) | (42,582) |
| Interest expense – related party | (14,559) | (15,313) |
| Interest expense related to revenue interest liability | (13,871) | (13,534) |
| Change in fair value of derivative liabilities | 1,108 | 5,578 |
| Interest expense | (34) | (18) |
| Other expense, net | (5,917) | (41) |
| Total other expense, net | (562,997) | (65,471) |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s interest expense?
- ImmunityBio, Inc. (IBRX) reported interest expense of $13.87M in Q1 2026.
- How has ImmunityBio, Inc.'s interest expense changed year-over-year?
- ImmunityBio, Inc.'s interest expense increased by 2.5% year-over-year, from $13.53M to $13.87M.
- What is the long-term trend for ImmunityBio, Inc.'s interest expense?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s interest expense has grown at a 36.5% compound annual growth rate (CAGR), from $14.85M to $51.54M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about ImmunityBio, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude